EUVIMEDEUVIMED entdecken
Crossref

Discovery and Structure–Activity Relationship of a Ryanodine Receptor 2 Inhibitor

Ryosuke Ishida, Xi Zeng, Nagomi Kurebayashi, Takashi Murayama, Shuichi Mori, Hiroyuki Kagechika

Chemical and Pharmaceutical Bulletin · 2024

DOI: 10.1248/cpb.c24-00114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical and Pharmaceutical Bulletin, 2024. Verfasst von Ryosuke Ishida und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU). Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Calcium Channel Blockers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ryanodine receptor 2 (RyR2) is a large Ca2+-release channel in the sarcoplasmic reticulum (SR) of cardiac muscle cells. It serves to release Ca2+ from the SR into the cytosol to initiate muscle contraction. RyR2 overactivation is associated with arrhythmogenic cardiac disease, but few specific inhibitors have been reported so far. Here, we identified an RyR2-selective inhibitor 1 from the chemical compound library and synthesized it from glycolic acid. Synthesis of various derivatives to investigate the structure-activity relationship of each substructure afforded another two RyR2-selective inhibitors 6 and 7, among which 6 was the most potent. Notably, compound 6 also inhibited Ca2+ release in cells expressing the RyR2 mutants R2474S, R4497C and K4750Q, which are associated with cardiac arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT). This inhibitor is expected to be a useful tool for research on the structure and dynamics of RyR2, as well as a lead compound for the development of drug candidates to treat RyR2-related cardiac disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelCalcium Channel BlockersHumansCalciumDose-Response Relationship, DrugDrug DiscoveryHEK293 CellsMolecular StructureStructure-Activity RelationshipAnti-Arrhythmia AgentsTachycardia, VentricularPolymorphic Catecholaminergic Ventricular Tachycardia

Stichwörter der Autor:innen

cyclobutanecarboxyl esterinhibitorryanodine receptor 2

Substanzen

CalciumRyanodine Receptor Calcium Release ChannelCalcium Channel BlockersAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU).
  • Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine.

Zitieren

APA

Ishida, R., Zeng, X., Kurebayashi, N., Murayama, T., Mori, S., & Kagechika, H. (2024). Discovery and Structure–Activity Relationship of a Ryanodine Receptor 2 Inhibitor. Chemical and Pharmaceutical Bulletin. https://doi.org/10.1248/cpb.c24-00114

Vancouver

Ishida R, Zeng X, Kurebayashi N, Murayama T, Mori S, Kagechika H. Discovery and Structure–Activity Relationship of a Ryanodine Receptor 2 Inhibitor. Chemical and Pharmaceutical Bulletin. 2024. doi:10.1248/cpb.c24-00114

BibTeX
@article{Ishida2024,
  author = {Ishida, Ryosuke and Zeng, Xi and Kurebayashi, Nagomi and Murayama, Takashi and Mori, Shuichi and Kagechika, Hiroyuki},
  title = {Discovery and Structure–Activity Relationship of a Ryanodine Receptor 2 Inhibitor},
  journal = {Chemical and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/cpb.c24-00114}
}
Kostenlos starten →